Article Information
- December 5, 2023.
Author Information
- Weiling Xu1,
- Yun Soo Hong2,
- Bo Hu3,
- Suzy A. A. Comhair1,
- Allison J. Janocha1,
- Joe G. Zein4,
- Ruoying Chen3,
- Deborah A. Meyers5,
- David T. Mauger6,
- Victor E. Ortega7,
- Eugene R. Bleecker5,
- Mario Castro8,
- Loren C. Denlinger9,
- John V. Fahy10,
- Elliot Israel11,
- Bruce D. Levy11,
- Nizar N. Jarjour12,
- Wendy C. Moore13,
- Sally E. Wenzel14,
- Benjamin Gaston15,
- Chunyu Liu16,
- Dan E. Arking2,*,
- Serpil C. Erzurum1,3,*,†,
- the National Heart, Lung, and Blood Institute (NHLBI) Severe Asthma Research Program (SARP),
- TOPMed mtDNA Working Group in NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium
- 1Department of Inflammation and Immunity
- 2McKusick-Nathans Institute, Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
- 3Department of Quantitative Health Sciences, Lerner Research Institute
- 4Respiratory Institute, Cleveland Clinic, Cleveland, Ohio
- 5Department of Medicine, University of Arizona, Tucson, Arizona
- 6Department of Public Health Sciences, Pennsylvania State University School of Medicine, Hershey, Pennsylvania
- 7Department of Internal Medicine, Division of Respiratory Medicine, Mayo Clinic, Scottsdale, Arizona
- 8Department of Medicine, University of Kansas School of Medicine, Kansas City, Kansas
- 9Division of Allergy, Pulmonary and Critical Care Medicine, University of Wisconsin, Madison, Wisconsin
- 10Department of Medicine, San Francisco School of Medicine, University of California, San Francisco, California
- 11Department of Medicine, Harvard Medical School, Boston, Massachusetts
- 12Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
- 13Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina
- 14Department of Environmental and Occupational Health, Graduate School of Public Health, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
- 15Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana
- 16Department of Biostatistics, School of Public Health, Boston University, Boston, Massachusetts
- ↵†Address correspondence to Serpil C. Erzurum, M.D. Cleveland Clinic 9500 Euclid Avenue, NC22 Cleveland, Ohio 44195, USA. Telephone: 216-445-6624 Fax: 216-636-0104 E-mail: erzurus{at}ccf.org
↵* Co-senior authors. Drs. Serpil C. Erzurum and Dan E. Arking contributed equally to this article.
Author Contributions: W.X., Y.S.H, A.J.J, D.E.A., and S.C.E. wrote the manuscript. W.X., Y.S.H., B.H., J.G.Z., R.C., and D.E.A. performed data analysis. S.A.A.C. managed samples and assays. S.A.A.C., J.G.Z., D.A.M., D.T.M., V.E.O., E.R.B., M.C., L.C.D., J.V.F., E.I., B.D.L., N.N.J., W.C.M., S.E.W., and B.G. were members of the Severe Asthmatic Research Program, recruited participants, and collected data. D.E.A. performed mitochondrial DNA copy number estimation in the UK Biobank. C.L. led the TOPMed mtDNA Working Group in NHLBI Trans-Omics for Precision Medicine (TOPMed) and supported mitochondrial DNA copy number estimation of Severe Asthma Research Program. V.E.O. led the TOPMed Asthma Working Group. All authors have read and agreed to the published version of the manuscript.
This research was conducted using the UK Biobank Resource under Application Number 17731. The study was supported by the National Heart, Lung, and Blood Institute (HL081064, HL103453, and HL144569) and the National Center for Advancing Translational Sciences (ULTR000439). SARP was supported by awards from the National Heart, Lung, and Blood Institute (U10 HL109172, U10 HL109168, U10 HL109152, U10 HL109257, U10 HL109046, U10 HL109250, U10 HL109164, U10 HL109086). SARP mitochondrial DNA copy numbers were from the Trans-Omics in Precision Medicine (TOPMed) program supported by the National Heart, Lung and Blood Institute (NHLBI). Core support including centralized genomic read mapping and genotype calling, along with variant quality metrics and filtering were provided by the TOPMed Informatics Research Center (3R01HL117626-02S1; contract HHSN268201800002I). Core support including phenotype harmonization, data management, sample-identity quality control, and general program coordination were provided by the TOPMed Data Coordinating Center (R01HL120393; U01HL120393; contract HHSN268201800001I).
SARP3 disclosure statement (industry): The following companies provided financial support for study activities at the Coordinating and Clinical Centers beyond the third year of patient follow-up: AstraZeneca, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Sanofi-Genzyme-Regeneron, and TEVA. These companies had no role in study design or data analysis, and the only restriction on the funds was that they be used to support the SARP initiative.
